US FDA Rejects Lung Disease Therapy of MannKind and United Therapeutics
The US FDA has rejected a lung disease therapy, which was developed by the United Therapeutics and the MannKind Corp, which has been citing an inspection issue at the third-party facility in the United States. On Monday, 18th October 2021, the draft label of the healthcare regulator for the drug, known as Tyvaso DPI, that […]
Continue Reading